USANA HEALTH SCIENCES INC
No SEC Form 4 filings for $USNA in the last 30 days.
See all $USNA insider activity →USANA Health Sciences (NYSE:USNA) reported Q2 CY2026 sales of $223 million, down 5.4% year on year, missing market expectations and sending the stock down 19.2% to $18.41. The company said full-year revenue guidance is $962.5 million at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was a $0.07 loss, better than consensus.
USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsreleaseex991.htm EX-99.1 Document USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (N
USANA Health Sciences (NYSE:USNA) is set to report Q2 earnings Tuesday after the bell. Last quarter, it reported $250.2M revenue, flat YoY, and beat analysts on EBITDA and EPS. For Q2, analysts expect flat YoY revenue, after a 10.8% rise last year. The article cites an average analyst price target of $39 versus $22.11.
Over the past 7 days, alphai's AI scored 3 news stories mentioning USNA (USANA HEALTH SCIENCES INC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.
Recent USNA coverage spans insider activity, earnings and financial news.
The miss on quarterly revenue and EPS shortfall likely drives near-term downside risk despite full-year revenue guidance beating estimates.
The guidance cut and impairment charge increase downside risk to earnings power and near-term sentiment, while the balance sheet remains cash-rich.
The piece is a pre-earnings setup, not a new earnings print. The main tradable risk is whether results and commentary beat or miss the flat revenue expectation.
The PR provides positive consumer-reported efficacy data for Glow, which may support marketing momentum but is not a financial guidance or regulatory milestone.
Routine insider selling disclosed via SEC Form 4; it may slightly affect sentiment but lacks evidence of fundamental change.
alphai scores every news story that mentions USNA with an AI model for sentiment and relevance, and aggregates insider trades from USANA HEALTH SCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
USANA Health Sciences (NYSE:USNA) reported Q2 CY2026 sales of $223 million, down 5.4% year on year, missing market expectations and sending the stock down 19.2% to $18.41. The company said full-year revenue guidance is $962.5 million at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was a $0.07 loss, better than consensus.
4 min readUSANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsreleaseex991.htm EX-99.1 Document USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (N
6 min readUSANA Health Sciences (NYSE:USNA) is set to report Q2 earnings Tuesday after the bell. Last quarter, it reported $250.2M revenue, flat YoY, and beat analysts on EBITDA and EPS. For Q2, analysts expect flat YoY revenue, after a 10.8% rise last year. The article cites an average analyst price target of $39 versus $22.11.
3 min readUSANA Health Sciences (NYSE: USNA) reported results from a 12-week consumer study of its Glow skincare supplement. The trial involved 36 participants in the US and Mexico. About 97.2% reported brighter-looking, more even-toned, and more radiant skin; 86.1% reported improved hydration, and 83.3% reported improved firmness and elasticity.
3 min readJones Paul A. (CHIEF PEOPLE OFFICER) sold 5,561 shares of USANA HEALTH SCIENCES INC (USNA) at $18.50 ($0.10M total) on 2026-06-08.
1 min readFleming John Turman sold 2,450 shares of USANA HEALTH SCIENCES INC (USNA) at $17.93 on 2026-06-01.
1 min readJones Paul A. (CHIEF PEOPLE OFFICER) sold 6,813 shares of USANA HEALTH SCIENCES INC (USNA) at $18.95 ($0.13M total) on 2026-05-28.
2 min readIIEKKING G DOUG (CHIEF FINANCIAL OFFICER) sold 5,360 shares of USANA HEALTH SCIENCES INC (USNA) at $18.75 ($0.10M total) on 2026-05-27.
1 min readFULLER GILBERT A sold 1,057 shares of USANA HEALTH SCIENCES INC (USNA) at $18.66 on 2026-05-22.
1 min readUSANA Health Sciences (NYSE:USNA) Director Gilbert Fuller sold 1,058 shares of company stock on March 20th, 2026, for a total of $17,986.00 at an average price of $17.00 per share. The stock traded down to $16.88, near its 52-week low, despite the company beating quarterly EPS expectations. Institutional investors hold over 54% of the shares, and analyst ratings are mixed.
3 min read
